Jurkat细胞
细胞生物学
T细胞
信号转导
激酶
癌症研究
贾纳斯激酶
MAPK/ERK通路
生物
化学
癌症免疫疗法
STAT蛋白
免疫疗法
T细胞受体
激活剂(遗传学)
细胞信号
自噬
蛋白激酶A
磷酸化
白细胞介素2受体
磷脂酶C
细胞毒性T细胞
PI3K/AKT/mTOR通路
ZAP70型
受体
白细胞介素3
作者
Yuantong Li,Haotian Tang,Wenhao Shi,Yu Zhou,Jiaxin Wen,Jingwen Zhu,Mingshan Gao,Tianfeng Xu,Hua Xie
标识
DOI:10.1016/j.intimp.2025.116026
摘要
Casitas B-lineage lymphoma-b (Cbl-b), an E3 ubiquitin ligase, is a novel rising cancer immunotherapy target negatively regulating T cell response, yet the effects of its pharmacological inhibition on T cell activation remain unexplored. Here, we present a systematic pharmacological analysis of Cbl-b inhibition in T cells using a selective small-molecule Cbl-b inhibitor (Cbl-bi) which targets Cbl-b directly. Cbl-bi potentiates T-cell receptor (TCR) signaling in both Jurkat and primary murine T cells, as evidenced by increased phosphorylation of phospholipase C gamma 1 (PLCγ1) and extracellular signal-regulated kinase (Erk) and elevated interleukin-2 production following anti-CD3/CD28 stimulation. Transcriptomic profiling of Cbl-b-inhibited T cells revealed a pronounced activation and inflammatory signature, with enrichment of nuclear factor kB (NF-κB), mitogen-activated protein kinase (MAPK), and Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathways. Pharmacological interrogation of downstream signaling demonstrated that MAPK pathway activity is essential for the enhanced activation conferred by Cbl-b inhibition. Moreover, co-inhibition of autophagy or hematopoietic progenitor kinase 1 (HPK1) synergistically amplified the pro-activation effect of Cbl-b inhibition. Collectively, these findings provide mechanistic insight into Cbl-b's immunosuppressive role and identify rational combination strategies targeting Cbl-b, autophagy, or HPK1 to robustly potentiate T cell function for immunotherapy of cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI